BAX icon

Baxter International

31.15 USD
-0.73
2.29%
At close May 13, 4:00 PM EDT
After hours
31.14
-0.01
0.03%
1 day
-2.29%
5 days
3.87%
1 month
9.76%
3 months
1.73%
6 months
-4.54%
Year to date
6.46%
1 year
-12.08%
5 years
-63.59%
10 years
-54.26%
 

About: Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Employees: 38,000

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

3.55% more ownership

Funds ownership: 90.85% [Q3] → 94.4% (+3.55%) [Q4]

9% less funds holding

Funds holding: 879 [Q3] → 803 (-76) [Q4]

15% less call options, than puts

Call options by funds: $91.6M | Put options by funds: $108M

20% less capital invested

Capital invested by funds: $17.6B [Q3] → $14.1B (-$3.5B) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]

26% less repeat investments, than reductions

Existing positions increased: 243 | Existing positions reduced: 329

34% less first-time investments, than exits

New positions opened: 110 | Existing positions closed: 167

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$28
10%
downside
Avg. target
$36
16%
upside
High target
$42
35%
upside

5 analyst ratings

positive
40%
neutral
40%
negative
20%
Morgan Stanley
Patrick Wood
53% 1-year accuracy
8 / 15 met price target
10%downside
$28
Underweight
Maintained
5 May 2025
Wells Fargo
Larry Biegelsen
37% 1-year accuracy
15 / 41 met price target
6%upside
$33
Equal-Weight
Maintained
2 May 2025
Barclays
Matt Miksic
56% 1-year accuracy
22 / 39 met price target
32%upside
$41
Overweight
Maintained
10 Mar 2025
Goldman Sachs
David Roman
41% 1-year accuracy
9 / 22 met price target
35%upside
$42
Buy
Reinstated
26 Feb 2025
JP Morgan
Robbie Marcus
55% 1-year accuracy
11 / 20 met price target
16%upside
$36
Neutral
Maintained
21 Feb 2025

Financial journalist opinion

Based on 13 articles about BAX published over the past 30 days

Neutral
Seeking Alpha
5 days ago
The 'Goldilocks' Case For Baxter International
Baxter International's stock has been challenging to own for the past decade, initially due to high valuations and later due to execution concerns and an ugly acquisition. During the pandemic, health care stocks, including Baxter, underperformed expectations, with BAX peaking in April 2020 before declining. But the divestiture of the kidney care business will help the balance sheet, and management is optimistic toward 2025 performance.
The 'Goldilocks' Case For Baxter International
Neutral
Business Wire
1 week ago
Baxter Declares Quarterly Dividend
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on July 1, 2025, to stockholders of record as of May 30, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagn.
Baxter Declares Quarterly Dividend
Neutral
Seeking Alpha
1 week ago
Baxter International Inc. (BAX) Q1 2025 Earnings Call Transcript
Baxter International Inc. (NYSE:BAX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President and Chief Investor Relations Officer Brent Shafer - Chairman and Interim Chief Executive Officer Heather Knight - Chief Operating Officer Joel Grade - Executive Vice President and Chief Financial Officer Conference Call Participants Joanne Wuensch - Citi David Roman - Goldman Sachs Travis Steed - BofA Securities Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Larry Biegelsen - Wells Pito Chickering - Deutsche Bank Danielle Antalffy - UBS Operator Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material.
Baxter International Inc. (BAX) Q1 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 week ago
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y
Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts.
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y
Positive
Benzinga
1 week ago
Baxter Reports Strong Medical Devices Sales In Q1, Lifts 2025 Guidance, Stock Jumps
On Thursday, Baxter International Inc. BAX reported a first-quarter 2025 adjusted EPS of 62 cents, beating the management guidance of 47 to 50 cents and the Wall Street estimate of 48 cents.
Baxter Reports Strong Medical Devices Sales In Q1, Lifts 2025 Guidance, Stock Jumps
Neutral
Zacks Investment Research
1 week ago
Baxter (BAX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Baxter (BAX) Reports Q1 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
1 week ago
Baxter (BAX) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Baxter (BAX) Reports Q1 Earnings: What Key Metrics Have to Say
Positive
Reuters
1 week ago
Baxter tops quarterly estimates on strong demand for medical devices
Medical products maker Baxter International on Thursday beat Wall Street estimates for first-quarter revenue and profit, helped by the robust demand for its intravenous (IV) solutions and patient-monitoring systems.
Baxter tops quarterly estimates on strong demand for medical devices
Neutral
Business Wire
1 week ago
Baxter Reports First-Quarter 2025 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. “Our solid performance in the first quarter of 2025 reflects the ongoing impact of our transformation journey,” said Brent Shafer, chair and interim chief executive officer. “Baxter today is a more focused and agile organization, well positioned to drive enhanced value for patients, healthcare providers, customers and shareholders through our rei.
Baxter Reports First-Quarter 2025 Results
Positive
Zacks Investment Research
1 week ago
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
Charts implemented using Lightweight Charts™